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Objective:  Azathioprine (AZA) is recognized among immunosuppressive medications as 
relatively safe during pregnancy for women with systemic lupus erythematosus (SLE) requiring 
aggressive treatment.  This pilot study aimed to determine whether SLE therapy during 
pregnancy was associated with developmental delays in offspring. 
 
Methods:  This cohort study included SLE patients with at least one live birth post-diagnosis.  
Medical histories were obtained via interviews and chart review.  Multiple logistic regression was 
used to examine associations between SLE therapy during pregnancy and maternal report of 
special educational (SE) requirements (as proxy for developmental delays) among offspring.  
Propensity scoring (incorporating corticosteroid use, lupus flare, and lupus nephritis) was used 
to account for disease severity. 
 
Results:  Of 60 eligible offspring from 38 mothers, 15 required SE services, the most common 
indication for which was speech delay.  7 of the 13 (54%) children with in utero AZA exposure 
utilized SE services versus 8 of 47 (17%) non-exposed (p<0.05).  After adjustment for 
pregnancy duration, small for gestational age, propensity score, maternal education and 
antiphospholipid antibody syndrome, AZA was significantly associated with SE utilization 
occurring  from age 2 onward (OR 6.6, 95% CI 1.0, 43.3), and bordered significance for 
utilization at any age or age <2 years. 
 
Conclusions:  AZA exposure during SLE pregnancy was independently associated with 
increased SE utilization in offspring, after controlling for confounders. Further research is 
indicated to fully characterize developmental outcomes among offspring with in utero AZA 
exposure.  Vigilance and early interventions for suspected developmental delays among 
exposed offspring may be warranted.
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Significance and Innovations 
 
• Azathioprine exposure during SLE pregnancy in this study was independently associated 
with increased requirement for special educational services among offspring, after 
controlling for suspected confounders. 
 
• Increased vigilance and early intervention for suspected developmental delays among 
children born to mothers with SLE may be warranted, as early intervention is effective in 
improving long term functioning among affected children.  
 
• Our findings do not establish sufficient risk that AZA should be withheld in lupus pregnancy 
requiring immunosuppressive therapy, as active, untreated disease may result in worse 
maternal and fetal outcomes.
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Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disease associated with 
strong female preponderance and incidence that increases during the reproductive years1,2.  .  
Due in large part to improved disease management, morbidity and mortality for SLE patients 
over the last several decades has decreased, providing more women with SLE the opportunity 
to achieve successful pregnancies3.   
 
Among immunomodulators used for SLE, azathioprine (AZA), hydroxychloroquine, cyclosporine 
and glucocorticoids are considered relatively safe for use during pregnancy4, while others 
(cyclophosphamide, methotrexate, mycophenolate mofetil) are contraindicated, especially 
during the first two trimesters.  However, little is known about long term effects on children born 
to mothers with SLE who were treated with these medications during pregnancy. Concerns 
have been raised that neurocognitive outcomes in these children may be influenced by maternal 
SLE disease activity and its treatment during pregnancy5-10. 
 
We performed this study to investigate potential risk factors for increased utilization of special 
educational (SE) services, as a proxy for developmental delays, among offspring of mothers 
with SLE, and in particular to identify novel associations with specific features of lupus or its 
treatment during pregnancy. 
 
 
PATIENTS AND METHODS   
 
Study population 
Women attending rheumatology outpatient clinics at the University of Michigan, and participants 
in the Michigan Lupus Cohort (MLC), were enrolled between December 2008-November 2010.  
Patients were eligible if they met ≥4 American College of Rheumatology (ACR) criteria for SLE 
11,12 prior to at least one pregnancy, and had at least one live birth following SLE diagnosis, with 
year of delivery occuring from 1993 onward.  This research was approved by the University of 
Michigan Institutional Review Board; written informed consent was obtained from the mothers 
and assent or consent of the offspring was obtained for children aged 10-17 years old. 
 
Data collection 
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Data were collected from the mothers through a structured interview with a study team member, 
as well as medical record review. The following information was obtained:  
 
Maternal medical and obstetric history.  Data including SLE disease duration, history of 
disease manifestations (e.g., lupus nephritis, hypertension), and history of antiphospholipid 
antibody syndrome (APS) defined according to published criteria12,13 were recorded.  Medication 
exposures were recorded, including details on fluorinated and non-fluorinated corticosteroids 
(non-fluorinated considered high dose if average daily dose was >20mg for majority of 
pregnancy).  An additional “significant steroid” variable was derived to combine exposures likely 
to cross the placenta into one category (>20 mg/d non-fluorinated steroids or fluorinated 
steroids)13. Laboratory profiles, including antiphospholipid antibodies and renal biopsies data 
were also recorded. 
 
Childrens’ medical and developmental history.  Antenatal complications and delivery 
information, as well as medication use at conception and during pregnancy were recorded.  
Childrens’ perinatal and pediatric general health histories were collected, including time spent in 
intensive care units, chronic medication exposures, frequency of infections (beyond typical 
childhood infections), and need for regular medical follow-up beyond pediatrician “well child” 
examinations.  Small for gestational age (SGA) was defined as neonatal birth weight below the 
10th percentile for gestational age, based on U.S. national reference data14.  The primary 
outcome was maternal report of developmental delay or utilization of SE services due to any 
significant lag in a child’s cognitive, physical or social maturity when compared with established 
age appropriate norms.  Included in this definition were delays in language and hearing, or any 
special educational need prompting referral by the child’s pediatrician or teacher for special 
educational services (e.g., occupational or speech therapy, behavioral counseling, tutoring).  In 
addition to collecting such data in open-ended fashion, we specifically collected data on 
attention deficit hyperactivity disorder (ADHD).  Delays were categorized according to whether 
they occurred during the first two years of life, and/or from age 2 years onward. 
 
Statistical analysis 
Baseline summary statistics were computed as mean and standard deviation or median and 
interquartile range for continuous variables, and frequency and proportion for categorical 
variables.  Non-parametric statistics were used if appropriate.  Demographic characteristics of 
mothers among the groups with and without SE service utilization were assessed for 
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comparability.  While the primary outcome was utilization of SE services occurring at any age 
during childhood, separate models were also examined according to SE requirement prior to 
age two years, and from age two years onward.  We compared baseline characteristics 
(including maternal and perinatal variables) among those children with and without SE utilization 
using Fisher’s exact and Wilcoxon rank-sum tests.  Adjustment for multiple comparisons was 
made by Šidák-Holm’s method15,16.  Multivariable logistic regression was used to adjust for 
potential confounders.  Variables judged to have clinical relevance based on a priori knowledge 
were retained in the final models regardless of significance.   
 
Since AZA use implies a need to treat active disease and/or maintain remission after moderate 
to severe disease manifestations, we derived a propensity score to account for potential 
confounding by indication.  Using multinomial logistic regression, we found the predicted 
probability of AZA treatment for each patient based on non-fluorinated corticosteroid dose 
during pregnancy, lupus nephritis (renal biopsy WHO Class III-V), and SLE flare during 
pregnancy.  This predicted probability was then used as a covariate in the multivariable logistic 
models examining the association between AZA and SE utilization.  Some mothers had more 
than one child included in the study; however, correlation was ignored in the primary results 
since the small sample size prohibited regression methods that take correlation into account.  
We therefore conducted sensitivity analyses, in which we ran a simulation on 1000 reduced 
samples that consisted of one randomly-selected child per mother, and examined the 
distribution of p-value from these models.  Statistical analyses were performed in Stata 11.1 





Eighty-five women were screened for the study, of whom 43 did not meet eligibility criteria, e.g., 
because pregancies occurred prior SLE diagnosis, and 4 were excluded due to inability to 
obtain outcomes data.  This analysis included data from the remaining 38 mothers and their 60 
eligible offspring.  Full medical records were available for 70% of the pregnancies.  The median 
age (IQR) of the offspring at the time of data collection was 5.7 (3.4, 9.2) years.  Maternal 
characteristics and SLE features are summarized in Table 1.  There were no significant 
differences in maternal age, race or level of education for mothers of the children with versus 
without SE requirement (data not shown).  Among the offspring, there were 56 singleton 
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pregnancies, and two twin sets (delivered at 30 and 36 weeks; no SE utilization occurred in the 
twins).  SE utilization was reported in 15 (25%) of the 60 children, with the most prevalent 
indication being speech delay (requiring speech therapy), in 12 of these 15 children. When 
categorized according to timing of delays, 10 of the 60 (17%) children received SE in the first 
two years of life, and 14 (23%) from age two onward; 9 children had SE requirement reported 
for both time periods.  The reasons for SE utilization are enumerated in Table 2. 
 
Maternal/fetal chracteristics among those requiring SE are presented in Table 3.  Several 
suspected confounders, including small for gestational age and maternal education, were not 
detected in this population to be associated with SE utilization at any age in univariate analyses.  
However, antiphospholipid antibody syndrome was significantly associated with with SE 
utilization at any age, and from 2 years of age onward.  Among maternal SLE therapeutics 
during pregnancy, corticosteroid dose and AZA were each associated in univariate analyses 
with a higher proportion of reported SE utilization among offspring with in utero exposure.  
When accounting for multiple comparisons, the adjusted p-value for AZA was p=0.08, whereas 
the adjusted value for non-fluorinated corticosteroids was p=0.4.  The proportions of SE 
utlization according to in utero AZA exposure are presented in Figure 1.  Overall, SE 
requirements were reported among 7 of 13 (54%) children with in utero AZA exposure versus 8 
of 47(17%) without AZA exposure  [univariate OR 5.69 (95% CI 1.50, 21.50); p<0.01].  In the 
first two years of life, 5 of the 13 (38%) children with in utero AZA exposure had SE requirement 
compared to 5 of 47 (11%) non-exposed children (p<0.05); from two years onward 7 of 12 
(58%) children with exposure had SE requirement compared to 7 of 47 (15%) with no exposure 
(p<0.01). 
 
Results from multivariable logistic regression models are presented in Table 4.  When adjusting 
for pregnancy duration, SGA, maternal education level, and maternal APS (Model A), in utero 
AZA exposure was associated with significantly increased SE utilization at any age, and for both 
subgroups (age <2 or ≥2 years), with odds ratios (ORs) ranging from 6.1-10.0.  When 
propensity score was added as a covariate (Model B), ORs for AZA were 4.4-6.6, with 
significance for SE utilization at age ≥2 years, and borderline significance for SE utilization at 
any age or <2 years (Table 4). 
 
We performed a sensitivity analysis to account for potential correlation due to multiple births 
from the same mother,  in which we ran a simulation on 1000 reduced samples that consisted of 
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one randomly-selected child per mother, modeling the outcome of SE utilization at any age (see 
methods).  From this simulation of models including propensity score, 22% of the 1000 random 
samples were significant at alpha of 0.1, lending support to conclusions based on models using 
the full sample size of 60 children. 
 
We performed a further sensitivity analysis restricted to the first-eligible offspring for each 
mother (n=38); to reduce the number of variables in this smaller model, we incorporated into the 
original propensity score the covariates from Model A.  Results from this sensitivity analysis 
were consistent with those from our primary analyses, though not reaching statistical 
significance in this reduced subset of the population [OR 2.5 (95% CI 0.3, 21.7) for delay at age 





In this pilot study, we found an association between maternal AZA therapy during pregnancy 
and SE utilization, a proxy for developmental delays, in offspring (particularly after age 2 years).  
This association remained significant when adjusting for recognized risk factors for learning 
disorders, e.g, prematurity and low birth weight18,19.  We did not find an increased risk for SE 
utilization among male offspring, as described in studies of dyslexia and learning delays among 
offspring of SLE mothers5-9,20,21. 
 
We controlled for dose of antenatal glucocorticoid exposure, both fluorinated and non-
fluorinated.  Fluorinated steroids (dexamethasone, betamethasone) cross the placenta, and 
have been linked to cognitive dysfunction in children after in utero exposure, including outside 
the setting of threatened premature delivery22.  Only two offspring in our study were exposed to 
fluorinated steroids, precluding ability to focus on this mode of therapy.  Non-fluorinated 
glucocorticoids cross the placenta at a much lower rate:  fetal exposure is regulated by placental 
11β-hydroxysteroid dehydrogenase which converts active cortisol into inactive cortisone13.  Most 
likely, ~10% of non-fluorinated glucocorticoid crosses into the fetal circulation at doses of ≤20 
mg13,23.  While in univariate analyses dose of non-fluorinated steroids was associated with SE 
requirement, this was no longer significant when adjusting for multiple comparisons, nor in 
multivariable modeling (OR 1.04; 95% CI 0.95, 1.14). 
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Our study population included women with a wide range of lupus activity, a significant number of 
whom required immunosuppressive, antimalarial and/or glucocorticoid therapy during their 
pregnancies.  In the majority of cases, immunosuppressive therapy during pregnancy was with 
AZA (n=13). Two subjects had exposure to mycophenolate mofetil (MMF), one throughout first 
and second trimesters (prior to FDA Category D prescribing warning for MMF), and one at 
conception, at which time MMF was stopped.  No other maternal characteristic, with the 
exception of APS, predicted SE requirement in children.  
 
AZA has been used for over fifty years in solid organ transplantation and is used frequently for 
therapy of organ threatening autoimmune diseases.  For SLE, AZA  is considered both a steroid 
sparing agent and a “maintenance drug” for use after initial disease control is achieved with 
cyclophosphamide24.  While AZA is considered relatively safe during pregnancy, it remains 
listed as a category “D” drug by the FDA, indicating that potential benefits may warrant its use in 
pregnant women despite potential risks.  Studies of AZA and pregnancy outcomes from diverse 
patient populations (solid organ transplant, rheumatic disease, and inflammatory bowel disease) 
have revealed inconsistent results:  there are case reports of malformations occurring in AZA 
treated women, as well as rare reports of fetal immunologic abnormalities, including newborn 
hypogammaglobulinemia and pancytopenias, most of which normalize by 10 weeks25-29. Some 
studies have reported increased rates of spontaneous abortions, prematurity, intrauterine fetal 
growth retardation and low birth weight, 27-29 but these studies often include patient populations 
with heterogenous and sometimes poorly controlled underlying diseases.  Thus findings may be 
confounded due to heightened disease activity or to concomitant medications required during 
pregnancy.  Other studies in inflammatory bowel disease and transplant populations have found 
no association between maternal AZA use and poor perinatal outcomes30-33.  In experimental 
animals, however, 6-mercaptopurine (6-MP), an AZA metabolite, has been found to be 
teratogenic at doses similar to or greater than the therapeutic doses used in humans34.  
 
AZA and 6-MP inhibit synthesis of DNA and RNA precursors adenine and guanine, thereby 
exerting immunosuppressive and anti-inflammatory effects by stopping proliferation of rapidly 
dividing immune cells34.  As administered, AZA is inactive, requiring non-enzymatic and 
enzymatic intracellular metabolism to its active metabolites, primarily 6-MP, and other inactive 
metabolites. 6-MP in turn is metabolized to active metabolites 6-thioguanine (6-TG) and 6-
methylmercaptopurine (6-MMP). 6-TG, has been demonstrated in fetal red blood cells at slightly 
lower concentrations than in the red blood cells of their mothers, who were treated with AZA 
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throughout their pregnancies for Crohn’s disease35. However, the investigators in that study did 
not detect 6-MMP in fetal circulation, nor were any teratogenic effects noted.  The authors 
concluded that the presence of measurable levels of one pharmacologically active thiopurine 
metabolite (6-TG) but not another (6-MMP) may indicate that the placenta forms a “relative 
barrier” to AZA and its metabolites, and recommended that a maternal level of 6-TGN (6-
thioguaninenucleotides) be obtained during pregnancy in women treated with AZA to assure 
that the fetus is not exposed to high levels of this metabolite. However, in their series, the 
highest maternal 6-TGN level observed was 291pmol/8 x 108 RBC corresponding to 6-TGN 
levels in the artery and vein of the umbilical cord of 65pmol/8 x 108 RBC and 93 pmol/8 x 108 
RBC, respectively, all of which are reassuringly lower than current recommended therapeutic 
levels for AZA treatment of 235-400 pmol/8 x 108 RBCs36 37. 
 
The possibility that thiopurine metabolites exert adverse effects on the developing fetus cannot 
be excluded.  AZA has not been definitively linked to birth anomalies or other complications of 
pregnancy, and understanding of the intrauterine effects of AZA and its metabolites is clearly 
incomplete.  Therefore our findings of significantly higher rates of SE utilization in children with 
in utero AZA exposure compared to those without exposure must be interpreted in the context 
of this uncertainty.  It is possible that AZA metabolites may have some effect on fetal nervous 
system development, manifesting in early childhood as impairment in speech or hearing, or 
delayed learning.  Alternatively, AZA may act as a marker of disease-related phenomenon. 
 
After controlling for several potential confounders, the association of AZA exposure and SE 
requirement in offspring remained significant.  While we cannot exclude the possibility of 
confounding by indication, we attempted to account for underlying disease severity by utilizing 
propensity scoring, and results from our models adjusting for propensity score support an 
independent association between AZA exposure and SE requirement in these children.  
 
Several methodologic considerations in our study are noteworthy.  First, the retrospective nature 
of the data acquisition regarding childhood SE requirement and developmental delays may have 
resulted in recall bias. However, because all of the mothers in this study had chronic disease 
and were unaware of specific hypotheses under investigation, we do not expect recall bias to 
have been different based on exposure to a specific therapeutic agent.  While a number of 
maternal and fetal characteristics were examined in univariate fashion, we did not formally 
adjust for multiple comparisons, as this was a pilot study intended to inform the design of a 
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larger, prospective study.  It will be important to replicate the results related to AZA exposure in 
an independent population.  Our small sample size limited the ability to account for correlations 
between offspring from the same mother, therefore separate models which randomly selected 
for one child from each mother were constructed, albeit further reducing the sample size.  A 
larger sample size would be necessary to investigate critical windows of susceptibility to AZA 
exposure during gestation that may be relevant to long-term developmental outcomes.  There 
was also a large degree of overlap among different categorizations of delays, i.e., many children 
with a delay or special need in their first two years of life also had ADD or an educational need 
later on, and were included in both categories.  Therefore, significance across multiple 
categorizations for a given characteristic is expected.  Another limitation was the inability to 
perform formal standardized testing in the full study cohort using validated instruments, which 
would more fully characterize the developmental spectrum and result in less susceptibility to 
referral biases that may exist for reasons such as provider practice or geographic location.  For 
example, preliminary data from the UK indicated only 2 cases of learning difficulties among 132 
offspring of SLE mothers38, in contrast to the larger proportion in our study (15 of 60 children) 
requiring SE services for learning or developmental delays.  Prospective studies with 
standardized testing would enable comparisons between study populations such as children 
born in the UK vs US.  Finally, due to the non-randomized nature of this study, it is not feasible 
to completely exclude the possibility that disease characteristics or severity may underlie the 
observed association between maternal AZA use and SE requirement in offspring, despite our 
attempts to account for the possibility of confounding by indication.  For example, we were 
unable to assess longitudinal patterns of disease activity measures during the course of 
pregnancy, and use of propensity scoring is an imperfect way to disentangle the effects of 
underlying disease and its treatment. 
 
Strengths of this study include access to a well characterized cohort of patients who were 
motivated and interested in participating in research.  As all patients were followed at the 
University of Michigan, laboratory assays were standardized.  The multidisciplinary research 
team included rheumatologists and a high risk obstetrician who brought in-depth knowledge of 
complicated pregnancies and perinatal risks to the review of each case.  In addition, the proxy 
variable for developmental delays – maternal report of SE utilization – represented a clinically 
relevant endpoint which was apparent to a provider, and prompted intervention. 
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The association detected in this pilot study between SE needs and in utero exposure to AZA 
warrants further prospective study of developmental delays.  We wish to emphasize that 
immunosuppressive therapy should not be withheld in lupus pregnancies when indicated for 
treatment of active disease, as highly active lupus during pregnancy is associated with poor 
fetal outcomes, including increase in premature birth rates and decrease in live births39 40.  Our 
findings should alert pediatric providers to consider the need for early developmental screening 
of children born to mothers with SLE.  Early identification of developmental delays, even during 
infancy, has been shown to increase long term functioning of affected children with appropriate 
intervention and treatment41-43.  With increasing numbers of women with lupus achieving 
successful pregnancies, increased vigilance and understanding of long term outcomes among 
their children will be important for patients and providers alike. 
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Table 1.  Maternal characteristics and SLE features (n=38 SLE patients) 
 
Characteristic 
No. (%) or 
median (IQR) 
Race  
African American 5 (13) 
White 25 (66) 
Asian 3 (8) 
Other 5 (13) 
Marital status  
Married 32 (84) 
Single/Div/Sep 6 (16) 
Maternal age at interview (years) 36.8 (32.2, 42.2) 
Maternal age at delivery (years)* 30.8 (27.8, 33.8) 
Maternal education (years) 16 (16, 18) 
Country of birth  
United States 34 (89) 
Other 4 (11) 
Number of pregnancies 2 (2, 3) 
Number of children 2 (1, 2) 
  
SLE features (ACR criteria)  
Malar rash 24 (63) 
Discoid rash 3 (8) 
Photosensitivity 24 (63) 
Oral ulcers 18 (47) 
Arthritis 36 (95) 
Serositis 15 (39) 
Renal Disorder 17 (45) 
Neurological disorder 11 (29) 
Hematological disorder 23 (61) 
Immunological disorder 31 (82) 
Antinuclear antibody (ANA) 34 (89) 
 
*unit of analysis is the delivery (n=60), since some women had more than one child included in 
this study
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Table 2.  Reported developmental delays or special educational utilization, stratified by 
age of occurrence, among 60 children of mothers with SLE.  Data expressed as frequency 
(percent). 
 







Age < 2 yrs 10 (17) 5 (39) 5 (11) 
Hearing impairment 1 (2) 1 (8) 0 (0) 
Fine motor skill deficit 2 (3) 1 (8) 1 (2) 
Gross motor skill deficit 1 (2) 1 (8) 0 (0) 
Speech delay 3 (5) 1 (8) 2 (4) 
Other 4 (7) 2 (15) 2 (4) 
    
Age ≥ 2 yrs 14 (23) 7 (54) 7 (15) 
Aid with reading 3 (5) 0 (0) 3 (6) 
Occupational therapy 2 (3) 1 (8) 1 (2) 
Speech therapy 11 (18) 6 (47) 5 (11) 
Attention deficit disorder 3 (5) 2 (15) 1 (2) 
 
* 4 children had more than 1 delay 
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Table 3.  Maternal/fetal characteristics and developmental delays/special educational 
needs among 60 children of mothers with SLE.  Data expressed as frequency (percent) or 
median (interquartile range). 
* p<0.10; ** p<0.05; *** p<0.01 (P-values correspond to comparison against the “no delay” 
group) 
† variable included in propensity score 
§ no patients were taking methotrexate or cyclophosphamide 
‡ fluorinated steroids (e.g., betamethasone, dexamethasone) administered for high risk of 
preterm labor 
**mycophenolate mofetil contraindicated during pregnancy
 No delay  Developmental Delay/SE utilization 
  
(n=45) 
 Any age 
(n=15) 
Age <2 yrs 
(n=10) 
Age > 2 yrs 
(n=14) 
SLE clinical features      
SLE duration (years) 9 (5, 12)  7 (2, 9) 8.5 (3, 10) 7.5 (2, 9) 
Antiphospholipid Ab Syndrome 4 (9)  5 (33)* 3 (30) 5 (36)** 
Lupus nephritis (renal biopsy 
WHO grade > III) † 
12 (27)  7 (47) 4 (40) 6 (43) 
SLE flare during pregnancy † 7 (16)  4 (27) 2 (20) 3 (21) 
Maternal hypertension 3 (7)  3 (20) 2 (20) 3 (21) 
Propensity score 0.14 (0.09, 
0.22) 






      
Medications during pregnancy 
§
      
Steroids, non-fluorinated      
None (0 mg) 21 (47)  5 (33)* 5 (50) 4 (29)** 
Low dose (1-15 mg) 23 (51)  6 (40)* 3 (30) 6 (43)** 
High dose (> 20mg) 1 (2)  4 (27)* 2 (20) 4 (29)** 
Steroids, fluorinated ‡ 1 (2)  1 (7) 1 (10) 1 (7) 
“Significant steroids”  (High dose 
or fluorinated) 
2 (4)  5 (33)*** 3 (30)* 5 (36)*** 
Azathioprine 6 (13)  7 (47)** 5(50)** 7 (50)*** 
Mycophenolate mofetil 2 (4)  0 (0) 0 (0) 0 (0) 
Hydroxychloroquine 23 (51)  7 (47) 5 (50) 6 (43) 
NSAIDs 1 (2)  0 (0) 0 (0) 0 (0) 
Anti-hypertensives 5 (11)  5 (33) 1 (10) 5 (36) 
      
Perinatal characteristics      
Preeclampsia 8 (18)  5 (33) 2 (20) 5 (36) 
Pregnancy duration      
<32 weeks 3 (7)  3 (20) 2 (20) 2 (14) 
32-36 weeks 12 (27)  5 (33) 3 (30) 5 (36) 
> 37 weeks 30 (67)  7 (47) 5 (50) 7 (50) 
Birth weight (kg) <2.5 kg 15 (33)  8 (53) 5 (50) 7 (50) 
Small for gestational age 11 (24)  4 (27) 2 (20) 4 (29) 
Sex of child (female) 18 (40)  5 (33) 3 (30) 5 (36) 
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Table 4.  Association between AZA use and special educational service utilization 
among children of SLE mothers.  Results from multivariable logistic regression 
models* 
 
 Model A 
without propensity score 
 Model B 
with propensity score** 
 OR (95% CI) p-value  OR (95% CI) p-value 
Any age  6.12 (1.3, 30.0) 0.025  4.4 (0.8, 25.3) 0.097 
Age < 2 yrs  6.18 (1.1, 36.4) 0.044  6.6 (0.9, 48.7) 0.065 
Age ≥ 2 yrs  10.0 (1.8, 56.3) 0.009  6.6 (1.0, 43.3) 0.048 
 
*All models adjust for maternal education level, duration of pregnancy, small for gestational age, 
and antiphospholipid syndrome.  
**Propensity score includes:  lupus nephritis, SLE flare during pregnancy, and non-fluorinated 
corticosteroid use (dose in mg) 
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Error bars represent Clopper-Pearson exact 95% confidence intervals 
 
“Any delay” represents delay occurring either within first 2 years of age or 2 years onward 
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